Wednesday, July 24, 2024 | Baltimore, MD

Biopharm I-Mab takes steps to become Rockville-based company

February 8, 2024

I-Mab, a global biotech company exclusively focused on bringing highly differentiated immunotherapies and biologics for cancer treatment, Wednesday announced that as part of its strategy to become a U.S.-based biotech with headquarters in Rockville, its Chinese subsidiaries have entered into definitive agreements with I-Mab Biopharma (Hangzhou) Co., Ltd., an unconsolidated affiliate of the company, and a group of China-based investors to divest the company’s assets and business operations in China.

Article Source: The Daily Record

The Morning Rundown

We’re staying up to the minute on the issues shaping the future. Join us on the newsletter of choice for Maryland politicos and business leaders. It’s always free to join and never a hassle to leave. See you on the inside.